DiaMedica Therapeutics (DMAC) Retained Earnings (2017 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Retained Earnings of -$182.8 million for Q1 2026, down 200.63% year-over-year from $181.7 million in Q1 2025, and down 5.81% quarter-over-quarter from -$172.8 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Retained Earnings (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$182.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 200.63% year-over-year to -$182.8 million; the TTM figure through Mar 2026 stood at -$182.8 million (down 200.63% YoY), while the FY2025 annual figure was -$172.8 million, down 195.61% from the prior year.
- Retained Earnings for Q1 2026 stood at -$182.8 million, down from -$172.8 million in the prior quarter.
- The five-year high for Retained Earnings was $215.6 million in Q3 2025, with the low at -$182.8 million in Q1 2026.
- The 5-year median for Retained Earnings is -$89.4 million (2022), against an average of -$5.9 million.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings tumbled 2978800.0% in 2022, then soared 264.79% in 2024.
- DiaMedica Therapeutics' Retained Earnings stood at $128.1 million in 2022, then sank by 190.22% to -$115.6 million in 2023, then soared by 256.37% to $180.7 million in 2024, then tumbled by 195.61% to -$172.8 million in 2025, then retreated by 5.81% to -$182.8 million in 2026.
- Business Quant data shows DMAC's Retained Earnings at -$182.8 million in Q1 2026, -$172.8 million in Q4 2025, and $215.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 231.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 231.32 Mn |
| Mar 31, 2026 | -182.80 Mn |
| Dec 31, 2025 | -172.77 Mn |
| Sep 30, 2025 | 215.60 Mn |
| Jun 30, 2025 | -155.41 Mn |
| Mar 31, 2025 | 181.66 Mn |
| Dec 31, 2024 | 180.70 Mn |
| Sep 30, 2024 | -132.10 Mn |
| Jun 30, 2024 | -125.80 Mn |
| Mar 31, 2024 | 167.10 Mn |
| Dec 31, 2023 | -115.56 Mn |
| Sep 30, 2023 | 166.15 Mn |
| Jun 30, 2023 | -105.90 Mn |
| Mar 31, 2023 | -101.40 Mn |
| Dec 31, 2022 | 128.08 Mn |
| Sep 30, 2022 | 127.67 Mn |
| Jun 30, 2022 | -89.37 Mn |
| Mar 31, 2022 | -86.01 Mn |
| Dec 31, 2021 | -82.50 Mn |
| Sep 30, 2021 | 126.30 Mn |